Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Tisotumab vedotin-tftv
Synonyms
Therapy Description

Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate consists of anti-tissue factor (TF) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces killing of tumor cells overexpressing tissue factor (PMID: 24371232, PMID: 31796521). Tivdak (tisotumab vedotin-tftv) is FDA approved fro use in patients with with recurrent or metastatic cervical cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tisotumab vedotin-tftv Tivdak HuMax-TF-ADC|TF-011-MMAE Tivdak (tisotumab vedotin-tftv) is an antibody-drug conjugate consists of anti-tissue factor (TF) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces killing of tumor cells overexpressing tissue factor (PMID: 24371232, PMID: 31796521). Tivdak (tisotumab vedotin-tftv) is FDA approved fro use in patients with with recurrent or metastatic cervical cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03438396 Phase II Tisotumab vedotin-tftv A Trial of Tisotumab Vedotin in Cervical Cancer Completed USA | ITA | ESP | DEU | BEL 3
NCT04697628 Phase III Topotecan Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 17
NCT03657043 Phase II Tisotumab vedotin-tftv A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208) Completed USA | ITA | ESP | BEL 2
NCT03485209 Phase II Tisotumab vedotin-tftv Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 1
NCT03245736 Phase II Tisotumab vedotin-tftv Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed USA | GBR 0


Additional content available in CKB BOOST